Demirci, E. Et Al. 2022. A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF level. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.78, no.7 , 1095-1104.

Demirci, E., Şener, E. F., Gül, M. K., Önal, M. G., & Dal, F., (2022). A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF level. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.78, no.7, 1095-1104.

Demirci, ESRA Et Al. "A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF level," EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.78, no.7, 1095-1104, 2022

Demirci, ESRA Et Al. "A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF level." EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.78, no.7, pp.1095-1104, 2022

Demirci, E. Et Al. (2022) . "A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF level." EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.78, no.7, pp.1095-1104.

@article{article, author={ESRA DEMİRCİ Et Al. }, title={A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF level}, journal={EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY}, year=2022, pages={1095-1104} }